1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Roche Opens New pRED Centre in Basel with an Investment of CHF 1.2 Billion

12 Sep 2024
Admin
News Article

Roche Opens New pRED Centre in Basel with an Investment of CHF 1.2 Billion

Roche opens new pRED Centre in Basel with an investment of CHF 1.2 billion to accelerate scientific innovation

Overview

Roche announced the opening of its new Pharma Research and Early Development (pRED) Centre at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000 state-of-the-art laboratory and office workplaces, the new centre brings together teams of scientists and researchers to accelerate scientific discoveries for patients.

From Roche Group

Severin Schwan, chairman of the Roche Group: “Roche has invested CHF 1.2 billion into the new pRED Centre, underscoring our ongoing commitment to supporting Switzerland in remaining a leading innovative life sciences hub, the country where Roche was founded over 125 years ago.”

From CEO of Roche Group

Thomas Schinecker, CEO of the Roche Group: “The new pRED Centre will play an integral role in collaborating with our research centres across the globe, aiming to boost the effectiveness and efficiency of our R&D, and to deliver the greatest impact for patients.”

From the pRED

Hans Clevers, head of pharma research and early development (pRED): “By investing in the new centre we are continuing to push scientific frontiers to translate innovation into medicines, to better meet the needs of our patients. The new centre will enable greater interaction and knowledge sharing across disciplines, for example, chemists, biologists and data scientists.”

About The new pRED Centre

The new pRED Centre consists of two high-rise laboratory buildings (114m, 72m), with cutting-edge lab technologies and digital solutions, alongside an office building and a convention centre (26m, 18m).
In total, there are 33 combined laboratories and office floors with 150 labs and workplaces for around 1,800 researchers.
The state-of-the-art buildings have been deliberately designed to foster collaboration and an end-to-end mindset, aiming to deliver the most transformative medicines to patients faster.
Investment by Roche
Since 2009, Roche invested 4.6 billion CHF into the Basel/Kaiseraugst site upgrade of which the inauguration of the pRED Centre marks the biggest single investment.
In addition, we are currently investing a further 1.2 billion CHF across the Basel site.
This totals an investment of 5.8 billion CHF into the development of the Basel/Kaiseraugst site from 2009 to 2030.

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.